The alliance between Patheon and Senopsys is intended to deliver patient accepted pediatric formulations, line extension products and reformulated pharmaceutical products.
These products will be optimized for palatability to increase patient compliance and improve health outcomes. Products with enhanced sensory characteristics such as smell, taste, texture, mouthfeel and appearance, ultimately can have a dramatic effect on whether a patient consistently adheres to the required dosing regimen.
Senopsys uses its proprietary FlavorMetrics sensory assessment tools to quantitatively measure the taste masking challenge of drug substances and the palatability of drug products. Using its FlavorOpt sensory optimization system, Senopsys applies its knowledge of sensory science, taste masking, flavor construction and excipient functionality to develop palatable drug products to meet the needs of specific patient populations.
Wes Wheeler, CEO of Patheon, said: “By creating this alliance with Senopsys, both companies can combine the proven history of Patheon’s experience in formulation development and quality with Senopsys’s expertise in taste assessment and optimization. The unique combination of innovative formulation and taste masking allows us to offer customers the potential to meet regulatory requirements and extend the patent life of their new drugs by six months.”